Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at Cantor's 2026 Global Healthcare Conference, scheduled for Sept. 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., will present on Sept. 10 from 3:55-4:25 p.m. ET. A live webcast and replay will be accessible through the Investors section of the Tonix website.
This participation is significant as it provides a platform for Tonix to discuss its recent milestones, particularly the approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), which is the first new treatment for fibromyalgia in over 15 years. The company's CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra. Tonix is also exploring TONMYA's potential in Phase 2 trials for major depressive disorder and acute stress disorder.
Beyond CNS, Tonix is advancing immunology programs that address high unmet needs. Notable pipeline candidates include TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection. Additionally, TNX-2900 is Phase 2 ready for Prader-Willi syndrome, a rare disease.
The conference appearance comes at a critical time for Tonix as it continues to maximize the science behind TONMYA and expand its pipeline. Investors and stakeholders will likely gain insights into the company's strategic direction and upcoming catalysts. The company's commitment to addressing areas of high unmet medical need in CNS and immunology positions it as a notable player in the biotech sector.
For more information about Tonix Pharmaceuticals, visit the company's newsroom at https://nnw.fm/TNXP.
